<DOC>
	<DOCNO>NCT01087840</DOCNO>
	<brief_summary>The use anti-HIV drug follow potential sexual inject drug use exposure HIV order try prevent exposure become infection common . This call nonoccupational postexposure prophylaxis ( NPEP ) . The likelihood NPEP succeed related intrinsic quality drug use include point life cycle HIV virus drug work , strong drug HIV , well tolerate drug i.e . side effect produce . Many people skip dose treatment abandon treatment side effect . The anti-HIV drug raltegravir work early life cycle virus i.e . integrate human DNA , potent HIV cause side effect . These quality make obvious choice use NPEP treatment . In study 100 HIV negative men receive raltegravir along another HIV drug call truvada ( commonly use NPEP ) 28 day possible sexual exposure HIV . They monitor closely adverse event , side effect ability take medicine day whole 28 day . The hypothesis study state raltegravir use NPEP safe , well tolerate result high treatment completion rate .</brief_summary>
	<brief_title>Raltegravir Use Nonoccupational Postexposure Prophylaxis ( NPEP ) Men Who Have Sex With Men</brief_title>
	<detailed_description>This single site , 72-week , prospective , open-label , non-randomized trial . One hundred 50 ( 150 ) eligible participant assign receive RAL 400 mg BID along tenofovir disoproxil fumarate/emtricitabine ( TVD ) 1 tablet daily ( 3-drug NPEP ) 28-days TVD 1 tablet daily ( 2-drug NPEP ) 28-days accord establish Australian guideline use 3 2-drug NPEP follow potential actual sexual exposure HIV men sex men ( MSM ) .1 Based hospital NPEP data past 2 year , anticipate 100 MSM receive 3-drug ( RAL-TVD ) NPEP 50 receive 2-drug ( TVD ) NPEP . Follow-up post NPEP 23 week i.e . week 24 post exposure . Primary study objective : To describe safety 28 day nonoccupational post-exposure prophylaxis ( NPEP ) contain raltegravir ( RAL ) To describe tolerability 28 day NPEP contain RAL To describe on-drug adherence regimen completion rate 28 day NPEP contain RAL Secondary study objective : To investigate whether receipt NPEP decrease , increase impact HIV risk take behaviour To describe effect RAL tenofovir disoproxil fumarate/emtricitabine ( TVD ) key inflammatory biomarkers subset main study population</detailed_description>
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Tenofovir</mesh_term>
	<mesh_term>Emtricitabine</mesh_term>
	<mesh_term>Raltegravir Potassium</mesh_term>
	<criteria>Eligible MSM , accord Australian NPEP guideline , opinion investigator , assess eligible NPEP follow potential actual sexual exposure HIV present St. Vincent 's Hospital , Sydney . Non sexual exposure Exposures occur sex man woman HIV infection diagnose baseline serological test include indeterminate serology consistent possible primary HIV infection Use medication contraindicate RAL TVD Serum hepatic transaminase ( ALT/AST ) great 5 time upper limit normal Serum creatinine great 2 time upper limit normal # Therapy adefovir , tenofovir , emtricitabine , lamivudine , entecavir hepatitis B Baseline serological evidence chronic/active hepatitis B Previous NPEP contain RAL study period A patient history current evidence condition , therapy , laboratory abnormality , circumstance might confound result study , interfere patient 's participation full duration study</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>April 2014</verification_date>
	<keyword>HIV</keyword>
	<keyword>nonoccupational</keyword>
	<keyword>postexposure</keyword>
	<keyword>prophylaxis</keyword>
	<keyword>HIV Seronegativity</keyword>
</DOC>